{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Prostate+Cancer&page=3", "query": { "condition": "Metastatic Prostate Cancer", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 1272, "total_pages": 128, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Prostate+Cancer&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Prostate+Cancer&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T09:49:29.244Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06705686", "title": "Novel ACK1 Inhibitor (R)-9b in Patients With Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Castration-resistant Prostate Cancer (CRPC)", "Metastatic Castration-resistant Prostate Carcinoma" ], "interventions": [ { "name": "(R)-9bMS", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TechnoGenesys, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 40, "start_date": "2026-03-13", "completion_date": "2028-03-30", "has_results": false, "last_update_posted_date": "2026-03-20", "last_synced_at": "2026-10-22T09:49:29.244Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT06705686" }, { "nct_id": "NCT02286921", "title": "Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration Resistant Metastatic Prostate Cancer" ], "interventions": [ { "name": "Testosterone cypionate", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Testosterone Enanthate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "MALE", "summary": "18 Years to 80 Years · Male only" }, "enrollment_count": 222, "start_date": "2015-01", "completion_date": "2020-02-21", "has_results": true, "last_update_posted_date": "2020-11-06", "last_synced_at": "2026-10-22T09:49:29.244Z", "location_count": 17, "location_summary": "Birmingham, Alabama • Duarte, California • Aurora, Colorado + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02286921" }, { "nct_id": "NCT05939414", "title": "An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Oligometastatic Prostate Cancer (OMPC)" ], "interventions": [ { "name": "AAA617", "type": "DRUG" }, { "name": "piflufolastat (18F)", "type": "DRUG" }, { "name": "gallium (68Ga) gozetotide (25μg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "MALE", "summary": "18 Years to 100 Years · Male only" }, "enrollment_count": 450, "start_date": "2024-03-12", "completion_date": "2031-10-03", "has_results": false, "last_update_posted_date": "2026-10-21", "last_synced_at": "2026-10-22T09:49:29.244Z", "location_count": 39, "location_summary": "Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 30 more", "locations": [ { "city": "Fayetteville", "state": "Arkansas" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05939414" }, { "nct_id": "NCT05479578", "title": "Cyclophosphamide and Dexamethasone for the Treatment of Metastatic Castration Resistant Prostate Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma", "Stage IVB Prostate Cancer American Joint Committee on Cancer (AJCC) V8" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rashmi Verma, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 7, "start_date": "2022-06-29", "completion_date": "2025-05-01", "has_results": false, "last_update_posted_date": "2025-01-08", "last_synced_at": "2026-10-22T09:49:29.244Z", "location_count": 1, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05479578" }, { "nct_id": "NCT02043678", "title": "Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Prostatic Neoplasms" ], "interventions": [ { "name": "Radium-223 dichloride (Xofigo, BAY88-8223)", "type": "DRUG" }, { "name": "Matching placebo (normal saline)", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone/Prednisolone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 806, "start_date": "2014-03-30", "completion_date": "2024-02-08", "has_results": true, "last_update_posted_date": "2025-02-19", "last_synced_at": "2026-10-22T09:49:29.244Z", "location_count": 29, "location_summary": "Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Oceanside", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02043678" }, { "nct_id": "NCT07287150", "title": "A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Castration-Resistant Prostate Cancer" ], "interventions": [ { "name": "Inavolisib", "type": "DRUG" }, { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 100, "start_date": "2026-03-11", "completion_date": "2029-07-30", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-22T09:49:29.244Z", "location_count": 6, "location_summary": "Los Angeles, California • San Francisco, California • Iowa City, Iowa + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "The Bronx", "state": "New York" }, { "city": "Providence", "state": "Rhode Island" } ], "official_url": "https://clinicaltrials.gov/study/NCT07287150" }, { "nct_id": "NCT02601014", "title": "Biomarker-Driven Therapy With Nivolumab and Ipilimumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Expressing AR-V7", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer", "Recurrent Prostate Carcinoma", "Stage IV Prostate Adenocarcinoma" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Enzalutamide", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 32, "start_date": "2016-03-15", "completion_date": "2021-10-06", "has_results": true, "last_update_posted_date": "2022-02-03", "last_synced_at": "2026-10-22T09:49:29.244Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02601014" }, { "nct_id": "NCT05689021", "title": "CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Resistant Prostate Carcinoma", "Metastatic Prostate Adenocarcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Abiraterone Acetate/Niraparib", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 8, "start_date": "2024-03-05", "completion_date": "2026-07-02", "has_results": false, "last_update_posted_date": "2026-07-22", "last_synced_at": "2026-10-22T09:49:29.244Z", "location_count": 3, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05689021" }, { "nct_id": "NCT06244004", "title": "FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Castration-Sensitive Prostate Carcinoma", "Metastatic Prostate Carcinoma", "Stage IVB Prostate Cancer AJCC v8" ], "interventions": [ { "name": "Antiandrogen Therapy", "type": "DRUG" }, { "name": "Bone Scan", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Cytotoxic Chemotherapy", "type": "DRUG" }, { "name": "FDG-Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 125, "start_date": "2024-02-18", "completion_date": "2028-02-18", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-22T09:49:29.244Z", "location_count": 6, "location_summary": "Chicago, Illinois • DeKalb, Illinois • Geneva, Illinois + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "DeKalb", "state": "Illinois" }, { "city": "Geneva", "state": "Illinois" }, { "city": "Oak Brook", "state": "Illinois" }, { "city": "Orland Park", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT06244004" }, { "nct_id": "NCT03338790", "title": "An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "nivolumab", "type": "BIOLOGICAL" }, { "name": "docetaxel", "type": "DRUG" }, { "name": "enzalutamide", "type": "DRUG" }, { "name": "rucaparib", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 292, "start_date": "2017-12-19", "completion_date": "2025-01-10", "has_results": true, "last_update_posted_date": "2026-01-27", "last_synced_at": "2026-10-22T09:49:29.244Z", "location_count": 19, "location_summary": "Daphne, Alabama • Rancho Mirage, California • New Haven, Connecticut + 16 more", "locations": [ { "city": "Daphne", "state": "Alabama" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" }, { "city": "Marietta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT03338790" } ] }